Cingulate Inc.
Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is …
Biotechnology
US, Kansas City [HQ]
Strategy & Leadership
All directors and officers of Cingulate Inc. are sourced directly from the SEC or manually.
For the SEC we either use the Form 3/4/5 or, even better extract the compensation for each leader out of the audited proxy statement (DEF-14A).
Each datapoint refers the most recent appearance of the corresponding person.
Officers & BofD Beta
For the SEC we either use the Form 3/4/5 or, even better extract the compensation for each leader out of the audited proxy statement (DEF-14A).
Total Compensation
Shows the total compensation per mentioned executive and board director.Each datapoint refers the most recent appearance of the corresponding person.
- No data, only available if we have DEF 14A compensations in place -
Officers
| Name & Position | Research | Last Appearance | |||
|---|---|---|---|---|---|
| - No data available - | |||||
Board of Directors (BofD)
| Name & Position | Research | Last Appearance | |||
|---|---|---|---|---|---|
| - No data available - | |||||